SCHEMBL2902332

SCHEMBL2902332

Cc1ccc(CNc2ccc3c(Nc4cccnc4)cccc3n2)o1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.39
KMT2A Q03164 2/20 0.39
NPC1 O15118 1/20 0.39
RAD52 P43351 1/20 0.39
ALDH1A1 P00352 4/20 0.38
HPGD P15428 4/20 0.38
LMNA P02545 3/20 0.38
TSHR P16473 2/20 0.38
POLB P06746 2/20 0.38
KDM4E B2RXH2 2/20 0.38
CASP1 P29466 2/20 0.38
CASP7 P55210 2/20 0.38
HSD17B10 Q99714 2/20 0.38
MAPT P10636 2/20 0.38
ALOX12 P18054 1/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
PDE5A O76074 2/20 0.35
GRM5 P41594 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
HTT P42858 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2908410 0.89 NPC1 (0.46) RAB9AKMT2ANPC1ALDH1A1HPGD
SCHEMBL2908916 0.89 TGFBR1 (0.42) RAB9AKMT2ANPC1ALDH1A1HPGD
SCHEMBL2902528 0.87 RAB9A (0.40) RAB9AKMT2ANPC1RAD52ALDH1A1
SCHEMBL2903146 0.86 POLB (0.46) RAB9AKMT2ANPC1ALDH1A1TSHR
SCHEMBL2902288 0.84 HTT (0.40) RAB9AKMT2ANPC1ALDH1A1LMNA
SCHEMBL2901522 0.83 RAB9A (0.41) RAB9AKMT2ANPC1ALDH1A1HPGD
SCHEMBL2902008 0.83 LMNA (0.45) RAB9AKMT2ANPC1ALDH1A1HPGD
SCHEMBL2902265 0.82 NPC1 (0.40) RAB9ANPC1ALDH1A1HPGDLMNA
SCHEMBL2906805 0.81 NPC1 (0.46) RAB9AKMT2ANPC1ALDH1A1HPGD
SCHEMBL2907467 0.81 NPC1 (0.43) RAB9AKMT2ANPC1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825253-B2 2-aminoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2010-11-02 US disclosed
EP-2076495-B1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES HOFFMANN LA ROCHE (CH) 2010-08-18 EP disclosed
EP-2076495-A1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES F.HOFFMANN-LA ROCHE AG (CH) 2009-07-08 EP disclosed
WO-2008037626-A1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-03 WO disclosed
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES AR, ADRA2C, RCC2 RAB9A 1336/4885KMT2A 335/4885NPC1 1573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.